CDC7 Inhibition Impairs Neuroendocrine Transformation in Lung and Prostate Tumors through MYC Degradation

Scientists nominated CDC7 inhibition as a therapeutic strategy to constrain lineage plasticity, as well as to effectively treat neuroendocrine tumors de novo or after transformation.